Energy Veteran Will Leverage Experience to Help SHINE Continue to Commercialize Moly-99
MONONA, WI – May 15, 2014 SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes, announced today that James L. Connaughton has agreed to serve as a strategic advisor to management as SHINE continues its efforts to bring molybdenum-99 (moly-99) to market. Moly-99 decays into the diagnostic imaging agent technetium-99m (Tc-99m). Tc-99m’s extraordinary attributes make it the most commonly-used medical isotope on the planet– used in over 40 million medical imaging procedures per year. SHINE was founded to deploy a safe, cost- effective and environmentally friendly technology to produce medical isotopes, including the supply of moly-99 in the United States.
Mr. Connaughton is Executive Vice President with C3 Energy, which offers big data energy analytics solutions to utilities and to oil and gas companies. Prior to joining C3 Energy, Mr. Connaughton served as Executive Vice President and Senior Policy Advisor of Exelon Corporation, and Executive Vice President, Corporate Affairs, Public and Environmental Policy for Constellation Energy. From 2001 to 2009, Mr. Connaughton was Chairman of the White House Council on Environmental Quality. In this capacity, he served on President Bush’s staff as senior environment, energy and natural resources advisor and as director of the White House Office of Environmental Policy. He holds a bachelor’s degree from Yale University and a J.D. from Northwestern University School of Law.
“SHINE is a great story of American entrepreneurial innovation, in which industry and government come together to solve a looming national problem with significant public health and national security implications. With assistance from the federal government, supply agreements with industry, and the support of local partners, SHINE has created an effective public-private partnership to reliably serve the critical health needs of 20 million U.S. patients each year who depend on moly-99 for diagnosing and treating illnesses. SHINE will meet this urgent need by building a new manufacturing plant and creating new jobs in America, while eliminating the use of highly enriched uranium to make this essential medical product. I look forward to helping SHINE bring its technology to market to achieve these important goals,” said Mr. Connaughton.
“We are thrilled and very fortunate to add such a tremendously distinguished and successful person as a strategic advisor,” said Greg Piefer, Ph.D., founder and chief executive officer of SHINE. “Given Jim’s public and private sector experience, we are confident that his work will help SHINE move forward as we develop a safe and reliable source of medical isotopes.”